A clinical trial showing a stack of interventions, including metabolic therapies, can double median survival for aggressive cancers would become the standard of care.

“So if someone came along and said, "Look, we're going to do all the things. We're going to rub curcumin on people's testicles and do all the things that are anecdotally supposed to help and it takes median survival from 11 months to 27 months. Wow, that's huge. Oh, and by the way, it's going to reduce the burden of seizures and it's going to reduce the catastrophic, debilitating side effects of this tumor and its therapy. I mean, it's going to become the standard of care, but the trial has to be done.”